How to Choose an Executive Search Firm for Pharmaceuticals & Biotechnology Leadership Hiring

A specialist firm organises partners around sectors and runs material mandate volume in pharma and biotech; a generalist firm distributes pharma mandates across partners by availability. Verification is structural. Ask how many pharma or biotech CXO placements the firm has completed in the last twenty-four months, what percentage of annual volume that represents, which sub-verticals those placements covered (API, formulations, biotech, vaccines, CDMO, specialty), and which IPA, OPPI, or global-parent alumni networks the practice partner holds relationships in. A specialist answers in specifics within two minutes.

The strongest proxies are structural. Ask the firm to share anonymised summaries of its last three pharma CXO placements — the sub-vertical, regulatory footprint, shortlist size, time to close, and the status of the placed candidate at twelve and twenty-four months including inspection or launch outcomes. Ask for a written process document describing the weekly operating cadence and regulator-sequencing sub-track. Ask to speak with the partner who would run your mandate. A firm that produces all three within forty-eight hours has the operational discipline that predicts quality.

Four question sets separate capable firms from confident ones. First, sub-vertical specifics: name three placements across different sub-verticals in the last two years and describe the inspection or launch outcomes under the placed candidates. Second, process: what is the written weekly cadence and how does it sequence against inspection windows and filing deadlines? Third, assessment: how do you probe quality-posture, inspection-readiness discipline, and CAPA-and-remediation history beyond the CV? Fourth, commercials and post-placement: how are fees staged, what is the guarantee window, and what is the integration process past day thirty covering quality-team and regulator-relationship handover?

Heavily. Pharma is a sector where generalist coverage systematically under-sources because the sub-vertical fragmentation is broad, quality-posture variables are subtle, and regulator-register instincts are not learnable on one mandate. Global brand firms can win pharma mandates on relationship capital, but the mandate typically gets run by a partner whose sub-vertical depth is formed after the brief. A specialist partner with a smaller brand and a continuous pharma map will typically outperform. Category is a proxy. Partner is the unit of decision.

Four structural differences. First, regulatory register is multi-jurisdictional and unforgiving — USFDA, EMA, PMDA, DCGI, WHO-PQ, and state DCA each impose ongoing inspection discipline, and a single observation can materially affect export-market positioning. Second, quality-posture and inspection-readiness discipline are hardest to assess and most consequential; CVs systematically over-communicate them. Third, sub-vertical fragmentation is broad and leader profiles do not interchange cleanly — API-to-formulations or generics-to-biosimilars transitions fail more often than CVs predict. Fourth, IP and trade-secret exposure during candidate transitions is legally consequential in ways most sectors do not carry. These shift the weight of Rules 1, 4, and 10 materially.

Five tests. First, has the firm placed comparable Site Heads or Quality Heads in the last twenty-four months and can it describe the inspection cycles the placed candidates have navigated post-placement? Second, does the assessment probe inspection-history directly, including specific scenarios on Form 483 response, CAPA escalation, and OAI remediation? Third, does the reference conversation include former Quality Heads, USFDA-alumni counterparts where discreet, and customer-quality leaders for CDMO mandates? Fourth, does the firm understand the difference between an oral-solids Site Head, an injectables Site Head, and a biosimilars Site Head? Fifth, does the firm carry returning-NRI coverage for Site Heads with global inspection experience, since the realistic US-inspection-proven pool is thinner domestically? A firm that treats the mandate as a standard operations-head search has not done the work.

Biotech and biosimilars mandates draw from a materially thinner pool than small-molecule CXOs and require different capability sets: R&D-platform judgement, partnership-ecosystem instinct, clinical-trial register, and evidence-generation commercial model. A credible firm distinguishes biotech-native from biotech-adjacent credentials in the longlist, probes clinical-trial and partnership history directly, and references with biotech-investor partners, global R&D counterparts, and biotech-peer CEOs. For specialty pharma specifically, the firm also maps KOL-engagement and medical-affairs register since specialty commercial models reward evidence-generation muscle more than volume-and-distribution muscle. Ask the firm to show its biotech or specialty-pharma map; genuine depth is visible inside two minutes.

Cross-sub-vertical pharma transitions fail most often on commercial-model and customer-register mismatch rather than technical capability. A generics-trained CEO moving to specialty must shift from price-and-distribution muscle to evidence-generation and KOL-engagement rhythm; an in-house-pharma leader moving to CDMO must learn customer-relationship register, multi-year contract economics, and technology-transfer discipline. A credible search firm names these dimensions in the briefing, tests through structured scenarios — "describe the last major launch or customer-onboarding cycle you led and how the commercial model shaped investment discipline" — and triangulates through references with peers who have made the same sub-vertical move. Firms that reduce pharma fit to chemistry at the interview table add no value to this specific risk.

A credible pharma CXO search typically runs eighty-five to one hundred and twenty days from mandate kick-off to signed offer, with another thirty to sixty days to onboarding through quality-team and regulator-relationship integration. Variation is driven by three factors. First, sub-vertical — a formulations COO search with a well-mapped pool reaches shortlist in five to six weeks; a biosimilars CSO or biotech R&D-Head search can need eight to ten weeks because the realistic pool is thinner. Second, regulatory footprint — US-export-oriented mandates require verified inspection history that narrows the pool. Third, brief clarity — mandates shifting mid-process on generics-versus-specialty weighting restart the clock.

A healthy pharma mandate draws from three channels. Direct approaches from continuous pharma-leader mapping produce sixty-five to seventy-five percent of the shortlist because senior leaders are heavily retained, IP-exposure-restricted, and insulated from inbound-recruiter engagement. Peer referrals from partner-level CEO, Site-Head, and R&D-leader relationships account for twenty to thirty percent. Database or active-applicant candidates are five percent or less — portal postings rarely reach the realistic pharma CXO tier.

Good-faith conduct is visible in three places. First, mapping depth — the firm produces a written longlist of forty to sixty pharma candidates considered, not only the four to six presented. Second, rejection reasoning — each longlist candidate carries a one-line reason recorded (e.g., "not pursued: strong formulations commercial record, insufficient inspection-cycle history for US-export-oriented mandate"). Third, disagreement — the firm pushes back when the brief is misaligned with the realistic pool, proposes adjacent sub-verticals when the mandate is ambiguously specified, and flags when compensation or equity is out of range.

Retained pharma search fees are a percentage of the hired executive's first-year total compensation — base, target bonus, and equity or long-term incentive — paid in three stages: engagement at kick-off, shortlist on presentation, and placement on acceptance. Contingency fees are success-only and generally lower, reflecting less upfront investment in sub-vertical mapping, inspection-history triangulation, and the quality-posture-and-IP-register probing this sector requires. For pharma CXO mandates, contingency is rarely the right model because the inspection-readiness assessment, CAPA-history probe, and customer-quality reference check are all time-expensive assessment hours a contingency model does not fund.

A credible pharma guarantee has three properties. First, a written tenure window — typically twelve months. Second, scope definition covering voluntary and mutual-separation outcomes, not only terminations for cause; pharma first-year exits surface disproportionately as negotiated departures triggered by quality-culture mismatch or regulator-register misalignment. Third, a structural backstop — fee portion held against twelve-month tenure or tied to completion of the first inspection cycle or major launch under the placed leader. Ask how the guarantee has been invoked on pharma mandates in the last twenty-four months.

Gladwin demonstrates Rule 1 in pharma through structural organisation and continuous sector work. The Pharmaceuticals & Biotechnology practice is led by a partner who runs it full-time, with placements spanning API and formulations, biotech and biosimilars, vaccines, CDMO and CRO, and specialty pharma. Across 16 years of Gladwin practice and 500+ C-suite placements firm-wide, 70+ have been pharma and biotech mandates.

Gladwin's approach to passive pharma talent (Rule 2) is built into how the practice operates between mandates. The pharma practice partner maintains a live map of approximately 140 leaders across sub-verticals, updated through peer-CEO conversations, IPA and OPPI interactions, CDSCO and USFDA alumni networks where discreet, global-pharma parent-HQ alumni channels, and biotech-investor networks. When a pharma role briefs, the partner already knows which leaders are worth approaching and which require a particular introduction route to protect IP-exposure and analyst-signalling sensitivity.

Gladwin runs a six-month post-placement integration cadence on every pharma mandate, calibrated to inspection-readiness cycles, filing deadlines, and launch commitments, and aligned to Rule 9. The cadence includes a week-two calibration with the CEO or Chairman, a month-one quality-team and regulator-relationship calibration, a month-three inspection-readiness or launch-readiness review, a month-six performance calibration against regulatory and commercial KPIs, and an off-ramp definition if friction is identified early.

The fastest path is the consultation form on this page — start here. Submissions are reviewed by the pharma practice partner within one business day, not by an associate. The form captures enough context (sub-vertical, regulatory footprint, timeline) to calibrate the initial thirty-minute call under mutual confidentiality. For sitting listed-pharma CEO or Site Head conversations, the confidentiality and IP-protection protocol engage from the first exchange. No information is retained or contacted beyond that call without explicit permission.

Four pieces of information calibrate the first conversation faster. First, the role and seniority level — CEO, COO, Chief Scientific Officer, Chief Quality Officer, Chief Regulatory Officer, Site Head, Head of Commercial, or functional CXO. Second, the sub-vertical and regulatory footprint — API, formulations, biotech, biosimilars, vaccines, CDMO, specialty; US-and-EU export-oriented, emerging-markets, India-only — because the partner assignment shifts accordingly. Third, the timeline. Fourth, one or two sentences on mandate context: succession, turnaround, inspection-cycle stabilisation, launch-readiness, or PE-portfolio professionalisation.